Literature DB >> 17982942

Immunizations in HIV-infected adults.

Pablo Rivas1, María Dolores Herrero, Sabino Puente, Germán Ramírez-Olivencia, Vincent Soriano.   

Abstract

The incidence or severity of certain vaccine-preventable diseases is higher in HIV-infected individuals. However, immune responses to vaccination may be diminished, particularly in those with severe immunosuppression. Higher doses of vaccine, more frequent boosters, or revaccination after antiretroviral therapy-induced immune reconstitution are strategies to be considered for patients in certain circumstances. In addition, some vaccines may be harmful when given to severely immunocompromised patients. The challenge for healthcare providers is assessing the safety and effectiveness of vaccines for HIV-infected patients, especially when information on vaccines has not been fully characterized in the HIV-setting. This review presents state-of-the-art knowledge about immunizations for HIV-adults. The efficacy and safety of current vaccines, their current indications in HIV-infected adults, and the strategies aimed to enhance their results are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982942

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  12 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 2.  An immunization update for HIV-infected adults in the United States: review of the literature.

Authors:  Patricia A Cioe; Kathleen Melbourne; Jerome Larkin
Journal:  J Assoc Nurses AIDS Care       Date:  2015 Mar-Apr       Impact factor: 1.354

Review 3.  Hepatitis B and human immunodeficiency virus co-infection.

Authors:  Bao-Chau Phung; Philippe Sogni; Odile Launay
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

4.  Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.

Authors:  Tsunamasa Watanabe; Susumu Hamada-Tsutsumi; Yoshiyuki Yokomaku; Junji Imamura; Wataru Sugiura; Yasuhito Tanaka
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 5.  Emerging challenges in managing hepatitis B in HIV patients.

Authors:  Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José M Peña; José V Fernández-Montero; Laura Benítez; Isabella Esposito; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

Review 6.  Optimal timing of routine vaccination in HIV-infected persons.

Authors:  Heidi M Crane; Shireesha Dhanireddy; H Nina Kim; Christian Ramers; Timothy H Dellit; Mari M Kitahata; Robert D Harrington
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

7.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 8.  Antibody-secreting B cells in HIV infection.

Authors:  Nicole A Doria-Rose; Mark Connors
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

9.  [Secondary immunodeficiency in rheumatological diseases].

Authors:  D Ernst; R E Schmidt; T Witte
Journal:  Z Rheumatol       Date:  2013-09       Impact factor: 1.372

10.  An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.

Authors:  Eva Van Braeckel; Patricia Bourguignon; Marguerite Koutsoukos; Frédéric Clement; Michel Janssens; Isabelle Carletti; Alix Collard; Marie-Ange Demoitié; Gerald Voss; Geert Leroux-Roels; Lisa McNally
Journal:  Clin Infect Dis       Date:  2011-01-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.